Genotype | n (%) | sTNF-RI (pg/ml) | sTNF-RII (pg/ml) |
|---|
Early RA |
TT | 63 (61.2) | 1,503 ± 704 | 4,690 ± 1,961 |
TG | 33 (32.0) | 1,451 ± 370 | 3,961 ± 1,242 |
GG | 7 (6.8) | 1,094 ± 240 | 3,648 ± 697 |
Established RA |
TT | 91 (60.3) | 1,816 ± 705 | 5,837 ± 2,219 |
TG | 51 (33.7) | 1,633 ± 642 | 5,375 ± 1,921 |
GG | 9 (6.0) | 1,700 ± 570 | 5,187 ± 1,066 |
- Shown are tumour necrosis factor receptor II (TNF-RII) T676G single nucleotide polymorphism (SNP) genotype frequencies and soluble tumour necrosis factor receptor (sTNFR) levels in rheumatoid arthritis (RA) patients with early (n = 103) and established (n = 151) disease. sTNFR levels are expressed as the mean ± standard deviation. Multiple regression analyses of log transformed data corrected for age, sex and disease duration revealed a significant trend of decreasing soluble tumour necrosis factor receptor I (sTNF-RI) and sTNF-RII levels across the genotypes (order: TT > TG > GG) of patients with established disease (P for trend = 0.01 and P for trend = 0.03, respectively). A similar nonsignificant trend was seen for patients with early disease (P = 0.3 and P = 0.055, respectively).
